ProQR Therapeutics (PRQR) Depreciation & Amortization (CF) (2013 - 2026)

ProQR Therapeutics has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $812497.5 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 13.93% year-over-year to $812497.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 6.77% YoY) and the FY2025 annual result came in at $3.1 million, up 6.64% from the prior year.
• Depreciation & Amortization (CF) grew to $812497.5 in Q1 2026 per PRQR's latest filing, from $790385.5 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $812497.5 in Q1 2026 and troughed at $589264.7 in Q1 2023.
• A 5-year average of $718960.7 and a median of $750676.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) fell 15.95% in 2022, then increased 27.39% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $763145.0 in 2022, then increased by 2.64% to $783284.3 in 2023, then declined by 8.46% to $717027.5 in 2024, then climbed by 10.23% to $790385.5 in 2025, then grew by 2.8% to $812497.5 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $812497.5, $790385.5, and $784436.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.